inclusion criteria: 1. patient with a history of laboratory proven-diagnosis of covid-19 who is 4-16 weeks from their last positive covid-19 test 2. systolic blood pressure ≥100 mmhg at screening 3. ≥18 years of age 4. successful collection of baseline serum biomarkers 5. successful completion of baseline eq-5d questionnaire 6. successful completion of baseline cmr study (cmr sub-study only) 7. high-sensitivity troponin t at or above the level of detection on screening labs 8. presence of ≥1 of the following: 1. age ≥60 2. history of atherosclerotic cardiovascular disease (ascvd), including myocardial infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or peripheral artery disease 3. diabetes mellitus (type 1 or type 2) 4. body mass index ≥35 kg/m2 5. egfr 30-60 ml/min/1.73m2 6. history of atrial fibrillation/flutter

inclusion criteria: 1. patient with a history of laboratory proven-diagnosis of covid-19 who is 4-16 weeks from their last positive covid-19 test 2. systolic blood pressure ≥100 mmhg at screening 3. ≥18 years of age 4. successful collection of baseline serum biomarkers 5. successful completion of baseline eq-5d questionnaire 6. successful completion of baseline cmr study (cmr sub-study only) 7. high-sensitivity troponin t at or above the level of detection on screening labs 8. presence of ≥1 of the following: 1. age ≥60 2. history of atherosclerotic cardiovascular disease (ascvd), including myocardial infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or peripheral artery disease 3. diabetes mellitus (type 1 or type 2) 4. body mass index ≥35 kg/m2 5. egfr 30-60 ml/min/1.73m2 6. history of atrial fibrillation/flutter

inclusion criteria: patient with a history of laboratory proven-diagnosis of covid-19 who is 4-16 weeks from their last positive covid-19 test systolic blood pressure ≥100 mmhg at screening ≥18 years of age successful collection of baseline serum biomarkers successful completion of baseline eq-5d questionnaire successful completion of baseline cmr study (cmr sub-study only) high-sensitivity troponin t at or above the level of detection on screening labs presence of ≥1 of the following: age ≥60 history of atherosclerotic cardiovascular disease (ascvd), including myocardial infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or peripheral artery disease diabetes mellitus (type 1 or type 2) body mass index ≥35 kg/m2 egfr 30-60 ml/min/1.73m2 history of atrial fibrillation/flutter

inclusion criteria: patient with a history of laboratory proven-diagnosis of covid-19 who is 4-16 weeks from their last positive covid-19 test systolic blood pressure ≥100 mmhg at screening ≥18 years of age successful collection of baseline serum biomarkers successful completion of baseline eq-5d questionnaire successful completion of baseline cmr study (cmr sub-study only) high-sensitivity troponin t at or above the level of detection on screening labs presence of ≥1 of the following: age ≥60 history of atherosclerotic cardiovascular disease (ascvd), including myocardial infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or peripheral artery disease diabetes mellitus (type 1 or type 2) body mass index ≥35 kg/m2 egfr 30-60 ml/min/1.73m2 history of atrial fibrillation/flutter

inclusion criteria: 1. patient with a history of laboratory proven-diagnosis of covid-19 who is 4-16 weeks from their last positive covid-19 test 2. systolic blood pressure ≥100 mmhg at screening 3. ≥18 years of age 4. successful collection of baseline serum biomarkers 5. successful completion of baseline eq-5d questionnaire 6. successful completion of baseline cmr study (cmr sub-study only) 7. high-sensitivity troponin t at or above the level of detection on screening labs 8. presence of ≥1 of the following: 1. age ≥60 2. history of atherosclerotic cardiovascular disease (ascvd), including myocardial infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or peripheral artery disease 3. diabetes mellitus (type 1 or type 2) 4. body mass index ≥35 kg/m2 5. egfr 30-60 ml/min/1.73m2 6. history of atrial fibrillation/flutter

inclusion criteria: 1. patient with a history of laboratory proven-diagnosis of covid-19 who is 4-16 weeks from their last positive covid-19 test 2. systolic blood pressure ≥100 mmhg at screening 3. ≥18 years of age 4. successful collection of baseline serum biomarkers 5. successful completion of baseline eq-5d questionnaire 6. successful completion of baseline cmr study (cmr sub-study only) 7. high-sensitivity troponin t at or above the level of detection on screening labs 8. presence of ≥1 of the following: 1. age ≥60 2. history of atherosclerotic cardiovascular disease (ascvd), including myocardial infarction, coronary artery disease, ischemic stroke/transient ischemic attack, or peripheral artery disease 3. diabetes mellitus (type 1 or type 2) 4. body mass index ≥35 kg/m2 5. egfr 30-60 ml/min/1.73m2 6. history of atrial fibrillation/flutter